CSL Invests $235 Million In Manufacturing Facility For Late-stage Development In Australia
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - CSL Limited announced July 16 that it will invest $235 million to expand its manufacturing site in Broadmeadows, Australia to create Victoria's first large-scale biotechnology facility for late-stage development of new therapies for cancer, bleeding disorders, inflammation and infections